162 related articles for article (PubMed ID: 28779652)
1. Varying the metal to ethacrynic acid ratio in ruthenium(ii)/osmium(ii)-p-cymene conjugates.
Păunescu E; Soudani M; Clavel CM; Dyson PJ
J Inorg Biochem; 2017 Oct; 175():198-207. PubMed ID: 28779652
[TBL] [Abstract][Full Text] [Related]
2. Highly Cytotoxic Osmium(II) Compounds and Their Ruthenium(II) Analogues Targeting Ovarian Carcinoma Cell Lines and Evading Cisplatin Resistance Mechanisms.
Hildebrandt J; Häfner N; Kritsch D; Görls H; Dürst M; Runnebaum IB; Weigand W
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563367
[TBL] [Abstract][Full Text] [Related]
3. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs.
Ang WH; De Luca A; Chapuis-Bernasconi C; Juillerat-Jeanneret L; Lo Bello M; Dyson PJ
ChemMedChem; 2007 Dec; 2(12):1799-806. PubMed ID: 17918761
[TBL] [Abstract][Full Text] [Related]
4. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
[TBL] [Abstract][Full Text] [Related]
5. Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity.
Peacock AF; Parsons S; Sadler PJ
J Am Chem Soc; 2007 Mar; 129(11):3348-57. PubMed ID: 17319668
[TBL] [Abstract][Full Text] [Related]
6. Organometallic osmium(II) arene anticancer complexes containing picolinate derivatives.
van Rijt SH; Peacock AF; Johnstone RD; Parsons S; Sadler PJ
Inorg Chem; 2009 Feb; 48(4):1753-62. PubMed ID: 19146436
[TBL] [Abstract][Full Text] [Related]
7. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Organometallic Osmium(II)-p-cymene Complexes.
Păunescu E; Nowak-Sliwinska P; Clavel CM; Scopelliti R; Griffioen AW; Dyson PJ
ChemMedChem; 2015 Sep; 10(9):1539-47. PubMed ID: 26190176
[TBL] [Abstract][Full Text] [Related]
9. Short divalent ethacrynic amides as pro-inhibitors of glutathione
Xu B; Tong T; Wang X; Liu F; Zhang X; Hu X; Li X; Yang X; Liao F
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):728-742. PubMed ID: 35176963
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and Anticancer Properties of Bifunctional Ruthenium(II)-p-Cymene Complexes: Influence of Pendant Perfluorous Chains.
Nowak-Sliwinska P; Clavel CM; Păunescu E; te Winkel MT; Griffioen AW; Dyson PJ
Mol Pharm; 2015 Aug; 12(8):3089-96. PubMed ID: 26158308
[TBL] [Abstract][Full Text] [Related]
11. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, characterization and biological evaluation of novel Ru(II)-arene complexes containing intercalating ligands.
Nikolić S; Rangasamy L; Gligorijević N; Aranđelović S; Radulović S; Gasser G; Grgurić-Šipka S
J Inorg Biochem; 2016 Jul; 160():156-65. PubMed ID: 26818702
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships for ruthenium and osmium anticancer agents - towards clinical development.
Meier-Menches SM; Gerner C; Berger W; Hartinger CG; Keppler BK
Chem Soc Rev; 2018 Feb; 47(3):909-928. PubMed ID: 29170783
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective anticancer activity of half-sandwich ruthenium and osmium complexes with modified curcuminoid ligands.
Pagliaricci N; Pettinari R; Marchetti F; Pettinari C; Cappellacci L; Tombesi A; Cuccioloni M; Hadiji M; Dyson PJ
Dalton Trans; 2022 Sep; 51(35):13311-13321. PubMed ID: 35983757
[TBL] [Abstract][Full Text] [Related]
15. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
16. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells.
Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V
Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087
[TBL] [Abstract][Full Text] [Related]
17. Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug.
Lee KGZ; Babak MV; Weiss A; Dyson PJ; Nowak-Sliwinska P; Montagner D; Ang WH
ChemMedChem; 2018 Jun; 13(12):1210-1217. PubMed ID: 29637702
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterisation and in vitro anticancer activity of hexanuclear thiolato-bridged arene ruthenium metalla-prisms.
Furrer MA; Garci A; Denoyelle-Di-Muro E; Trouillas P; Giannini F; Furrer J; Clavel CM; Dyson PJ; Süss-Fink G; Therrien B
Chemistry; 2013 Feb; 19(9):3198-203. PubMed ID: 23344898
[TBL] [Abstract][Full Text] [Related]
19. New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes.
Hotze AC; Bacac M; Velders AH; Jansen BA; Kooijman H; Spek AL; Haasnoot JG; Reedijk J
J Med Chem; 2003 Apr; 46(9):1743-50. PubMed ID: 12699392
[TBL] [Abstract][Full Text] [Related]
20. Chlorambucil conjugates of dinuclear p-cymene ruthenium trithiolato complexes: synthesis, characterization and cytotoxicity study in vitro and in vivo.
Stíbal D; Therrien B; Süss-Fink G; Nowak-Sliwinska P; Dyson PJ; Čermáková E; Řezáčová M; Tomšík P
J Biol Inorg Chem; 2016 Jul; 21(4):443-52. PubMed ID: 27040952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
